ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Shubick Committee Support New System for NCU Review, Action On Chemicals

November 14, 1975

Spectral Mammography “Like Color vs. Black & White TV”

August 31, 2012

FY 1984 Bypass Budget Shown By Mechanism,, Research Program

July 2, 1982

In Brief Yale Cancer Center Begins Reorganization, Names New Deputy Director, Prevention Chief

January 6, 1995

In Brief: CDP Services Wins ASC Planning Contract; Jury Finds Sarin Guilty of Embezzlement

July 17, 1992

Nexavar Phase III Trial Fails To Meet Primary Endpoint

June 29, 2012